March 26, 2026 09:10 ET  | Source: Royal Philips March 26, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution that assists physicians during one of interventional cardiology’s most […]

March 25, 2026 12:15 ET  | Source: Io Therapeutics, Inc. SPRING, Texas, March 25, 2026 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports – Nature, of collaborative studies with Duke University scientists on effects of the company’s anti-cancer compound IRX4204, on human multiple myeloma,

March 25, 2026 05:00 ET  | Source: Royal Philips March 25, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the launch of its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe. With CE marking and FDA 510(k) clearance, the

March 25, 2026 02:36 ET  | Source: Boehringer Ingelheim Limited Intended audience: global business, financial and trade media Ingelheim, March 25, 2026 – Boehringer Ingelheim successfully delivered on key launches in its Human Pharma business in 2025, bringing two medicines with FDA Breakthrough Therapy designation for lung cancer and pulmonary fibrosis to market in the second half

March 24, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 24, 2026 (GLOBE NEWSWIRE) — SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity, today announced a strategic partnership. This collaboration aims to integrate Prozomix’s extensive biocatalyst libraries into SK pharmteco’s small-molecule development and

March 24, 2026 04:30 ET  | Source: Royal Philips March 24, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it ranked No. 1 among medical technology companies in the European Patent Office’s (EPO) Technology Dashboard 2025. Medical technology is the most important domain for Dutch patent applications at the

March 24, 2026 02:00 ET  | Source: Sanofi Winthrop Industrie Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Paris and Tarrytown, NY, March 24, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults

New capability delivers seamless interoperability and global connectivity, laying the foundation for end-to-end regulatory integration March 24, 2026 01:00 ET  | Source: Accumulus Technologies SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) — Accumulus Technologies today announced the launch of the Accumulus Connector (“Connector”), a new platform capability that extends the Accumulus platform into customers’ existing technology stacks,

March 23, 2026 11:46 ET  | Source: ProductLife Group (PLG) PARIS, March 23, 2026 (GLOBE NEWSWIRE) — ProductLife Group (PLG), a global provider of consulting and outsourcing services for the life sciences industry, has appointed Dr. James Burt as Chief Executive Officer. Dr. Burt brings more than 20 years of international leadership experience across the pharmaceutical value

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia March 23, 2026 07:00 ET  | Source: PROCEPT BioRobotics SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male

March 23, 2026 05:30 ET  | Source: Royal Philips March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: The agenda furthermore includes a proposal

March 23, 2026 04:30 ET  | Source: Royal Philips March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President/CEO. The Supervisory Board will submit to the Annual General Meeting of Shareholders

March 19, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was

March 19, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following

March 19, 2026 09:00 ET  | Source: Curia Global, Inc. ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development. The Glasgow, UK,